Overview

A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at the effects of RN624 on moderate to severe knee pain due to osteoarthritis. This study will look at the safety and pain relieving effects of RN624 compared to placebo over a 4 month period.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Antibodies, Monoclonal
Tanezumab